Zanubrutinib Oral Capsule

DRUG3 trials

Sponsors

Stichting Hemato-Oncologie voor Volwassenen Nederland, The Lymphoma Academic Research Organisation, Azienda Ospedaliera di Padova

Conditions

Anti-MAG IgM-associated Demyelinating PolyneuropathyLymphomaLymphoma, Mantle-Cell

Phase 2

Zanubrutinib in Primary Cold Agglutinin Disease

Active, not recruitingNCT06067048

Stichting Hemato-Oncologie voor Volwassenen NederlandLymphoma

Start: 2024-07-26End: 2028-11-01Target: 25Updated: 2026-03-06

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

RecruitingNCT06558604

The Lymphoma Academic Research OrganisationLymphoma, Mantle-Cell

Start: 2025-02-21End: 2032-03-01Target: 100Updated: 2026-07-10

Zanubritnib and Anti-MAG Neuropathy

RecruitingNCT07392229

Azienda Ospedaliera di PadovaAnti-MAG IgM-associated Demyelinating Polyneuropathy

Start: 2026-03-24End: 2031-03-01Target: 50Updated: 2026-08-28